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1. Abstract 34 
Atopic dermatitis (AD) is a complex disease that is thought to be triggered by environmental 35 
factors in genetically susceptible individuals. Twin studies have estimated the heritability of 36 
AD to be approximately 75%, with the null (loss-of-function) mutations of the gene encoding 37 
filaggrin (FLG) (chromosome 1q21.3) as the strongest known genetic risk factor. The 38 
discovery of the filaggrin gene was important in the emerging model for AD pathogenesis, 39 
combining skin barrier function with adaptive and innate immunity. Assisted by recent 40 
development of large-scale high-throughput genomics, more than 30 genetic loci have been 41 
linked to AD across different populations. Identification of these loci, together with functional 42 
studies, has already provided new insights into disease biology and identified novel drug 43 
targets. Further, these susceptibility loci are laying the groundwork for phenome-wide 44 
association studies to test their multiple phenotype relationships and application of Mendelian 45 
Randomization to investigate causal relationships. Despite many known genes, a majority of 46 
the genetic risk for AD is yet unexplored. Therefore, studies investigating refined phenotype 47 
groups, low-frequency and rare genetic variation, gene-gene and/or gene-environment 48 
interactions, epigenetic mechanisms and data from multi-omics technologies are warranted. In 49 
this review we describe genetic discoveries for AD, including results from candidate gene 50 
studies, studies of AD-like genetic diseases, genome-wide association studies and genetic 51 
sequencing studies. We explain how some of these genetic discoveries have unraveled new 52 
mechanistic insights into the pathogenesis of AD and exemplifies how personal genetic data 53 
could be used for preventive strategies and tailored treatment regimen (i.e. precision 54 
medicine).  55 
 56 
2. Introduction 57 
Atopic dermatitis (AD, synonymous with 'atopic eczema') is a chronic inflammatory skin 58 
disease with a lifetime prevalence of 15-20% in developed countries [1, 2]. AD usually begins 59 
in early childhood, and in 70% of cases the disease manifests before five years of age [3]. The 60 
disease is characterized by dry skin, pruritus, and eczematous lesions, which can lead to 61 
intense itch, sleep deprivation, and diminished self-esteem [2]. The disease shows large 62 
clinical heterogeneity related to age, ethnicity and disease severity [4, 5]. Consequently, 63 
topical and systemic treatments are tailored to clinical need with the aim to manage symptoms 64 
and obtain long-term disease control [6, 7]. 65 
 66 
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AD is associated with atopic (asthma, allergic rhinitis, food allergies) and non-atopic (e.g. 67 
inflammatory diseases, phycological disturbances) comorbidities [8, 9]. For the atopic 68 
comorbidities, the association is strong, and family and genetic studies indicates a shared 69 
genetic susceptibility [10-12]. For the non-atopic comorbidities, the association is less clear, 70 
and underlying mechanisms are likely to be complex and involve common genetic 71 
susceptibilities, systemic inflammation, environmental exposures, medication and lifestyle 72 
factors [8]. 73 
 74 
A family history of atopic disease is the strongest known risk factor for AD [13]. This 75 
observation formed the rationale for genetic investigations to identify novel mechanisms 76 
leading to AD and related comorbidities. The search for new genetic risk factors is motivated 77 
by already highly successful discoveries in the field, and in particular by the identification of 78 
the filaggrin gene (FLG) in 2006 [14]. This completely changed the understanding of atopic 79 
diseases; from a purely immunological view, the initial pathogenesis is now known to include 80 
defects of the epidermal barrier, immunological dysregulation and triggering factors [2] and 81 
this have had implications for treatment strategies [15, 16].  82 
 83 
Substantial advances in the field of genetic epidemiology over the past two decades are laying 84 
the framework for new gene discoveries for complex diseases. One of the groundbreaking 85 
events in the field was when the Human Genome Project published the full human genome in 86 
2004 [17, 18]. Together with large population-based sample sizes, the innovation of cost-87 
effective microarray technology and new analytical tools, opened for large-scale high-88 
throughput genomics. The field has moved from candidate gene and family-based studies to 89 
large population-scale whole-genome genotyping including >1 million people and > 20 90 
million genetic variants [19].  91 
 92 
In this review, we summarize some of the known genetic associations of AD in relevance to 93 
the pathogenesis of the disease and illustrate how these associations can be used for phenome-94 
wide association studies (PheWAS) to test their multiple phenotype relationships and 95 
application of Mendelian Randomization (MR) to investigate causal relationships. An 96 
overview of some of the investigative strategies included in this paper is given in Figure 1. 97 
We focus primarily on research involving genetic studies and encourage the readers to study 98 
results from additional omics-data, i.e. epigenomics, transcriptomics, proteomics and 99 
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metabolomics in other publications [20-25]. Finally, we discuss future directions in the field 100 
including the potential avenues of precision medicine. 101 
 102 
3. Establishing a genetic component and gene discovery  103 
The heritability (the proportion of phenotypic variance due to genetic variance) of a disease or 104 
trait is usually estimated by observing patterns of inheritance among individuals either in 105 
family and twin studies or in population-based studies [26]. The first descriptions of familial 106 
aggregation of atopic skin disease goes 2,000 years back, when the Roman historian 107 
Suetonius described that Emperor Augustus (63 BC - 14 AD) had dry, itchy patches on his 108 
skin and suffered from a seasonal respiratory disorder, and both his grandson and his great 109 
grandnephew suffered from symptoms of atopy [27]. More recent family studies have 110 
indicated a three- to fivefold increased risk for a person to develop AD if one or both parents 111 
have a history of AD [13, 28]. Twin studies of AD show that monozygotic twins have 112 
approximately three times higher concordance rate than dizygotic twins [29]. A systematic 113 
review which included information from 35,155 twin pairs estimated the heritability of AD to 114 
be approximately 75% [29], which is considered to be a high heritability for a complex trait.  115 
 116 
3.1 Candidate gene studies. FLG. By far the strongest known genetic risk factor for AD is 117 
null (loss-of-function) mutations of the gene encoding filaggrin (FLG), a gene located in the 118 
epidermal differentiation complex on chromosome 1q21.3 [14, 30, 31]. Filaggrin has multiple 119 
interrelated functions contributing to skin barrier development and maintenance [30], and null 120 
mutations of FLG lead to truncation of profilaggrin and loss of filaggrin expression. 121 
Individuals with filaggrin deficiency experience an increased skin permeability, facilitating 122 
the effect of environmental allergens, irritants and microbes, and initiation of an inflammatory 123 
cascade. The link between FLG and AD was identified in 2006 when studying ichthyosis 124 
vulgaris [32], a genetic disease that displays AD-like characteristics. FLG was further 125 
associated with AD [14], a discovery that changed the view of the pathogenesis of AD. The 126 
focus shifted from an immunological view including imbalance of T-cells to inclusion of a 127 
functional disruption of the epidermal barrier as the primary pathogenic process [33]. About 128 
10% of the European and Japanese ancestry population carry a null mutation within FLG 129 
exon 3 and they have mild ichthyosis and a threefold increased risk of AD compared with the 130 
general population [2, 30]. This demonstrates a strong effect for a single gene in the context 131 
of a complex disease [34].  132 
 133 
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Other genes. Based on their theoretical role in disease pathogenesis, a large number of 134 
candidate gene studies have been performed to elucidate the genetic background of AD [20, 135 
35, 36]. This includes genes involved in epidermal differentiation, skin immunity, or systemic 136 
immunity [36]. Highlighted genes identified by candidate gene studies comprise the genes 137 
encoding interleukin (IL)-4, the IL-4 receptor, and IL-13 [37, 38], all lying in the Th2 138 
cytokine cluster on chromosome 5q31.1. This locus is also robustly associated with AD in 139 
genome-wide association studies (GWAS) (see below).  140 
 141 
3.2 Studies of AD-like genetic diseases. Detailed studies of genetic diseases that display AD-142 
like characteristics have provided insight into monogenic drivers of disease pathogenesis [39]. 143 
These studies have focused on diseases characterized by skin barrier dysfunction (e.g. 144 
ichthyosis vulgaris, generalized peeling skin, Netherton syndrome), multi-system atopic 145 
inflammation (e.g. Severe dermatitis, multiple Allergies and Metabolic wasting, SAM) and 146 
immunodeficiency with skin manifestations resembling AD (e.g. Hyper-IgE, Omenn 147 
syndrome) [39]. To illustrate; the syndrome of SAM is a rare (prevalence <1/1 million) 148 
genetic disease that shows AD-like manifestations including congenital erythroderma, 149 
superficial skin erosions, fine scales and palmoplantar keratoderma, food allergies and 150 
increased IgE levels. Whole-exome sequencing revealed homozygous loss-of-function 151 
mutations in DSG1 (encoding desmoglein) [40] and heterozygous mutation in DSP (encoding 152 
desmoplakin) [40, 41] that segregated with disease. The genetic mutations of SAM lead to 153 
compromised barrier function and DSG1deficiency was associated with increased expression 154 
of genes encoding allergy-related cytokines. This informed the knowledge of epidermal 155 
barrier dysfunctions leading to local and systemic atopic inflammation [40, 41].   156 
 157 
3.3 Genome-wide association studies (GWAS). GWAS is an experimental design used to 158 
test the association between thousands, and even millions, of genetic variants with a disease 159 
outcome or trait [42]. The primary aim of these studies is to increase the understanding of 160 
genetic risk of disease and provide a foundation for functional and mechanistic follow-up 161 
studies that will enable more effective detection, prevention and treatment. GWAS have 162 
proven successful at mapping areas on the human chromosomes (loci) that influence AD [43-163 
50], and since the first published study on AD in 2009 [43], >30 genetic loci have been 164 
identified, where the majority show a slight to moderate risk for disease development [47]. 165 
An overview of these loci, their likely candidate genes and known or proposed functions have 166 
recently been published [2, 4], including a review focusing on associations in diverse, non-167 
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European ethnic groups [4]. The first GWAS on AD was performed on a German population 168 
of 939 individuals with AD and 975 controls as well as on 270 complete nuclear families with 169 
two affected siblings, and their replication population included 2,637 cases and 3,957 controls 170 
[43]. They detected the FLG locus and identified a novel susceptibility locus on chromosome 171 
11q13.5 (top hit rs7927894), an intergenic region of unknown function. The study found that 172 
approximately 13% of individuals with European ancestry are homozygous for rs7927894, 173 
and that their risk to develop AD is 1.47 times that of non-carriers [43]. Subsequent GWAS 174 
replicated the FLG and chromosome 11q13.5 loci across different populations, and added 175 
several new loci associated with AD risk. The majority of GWAS loci identified are involved 176 
in skin barrier development and immunological dysfunctions, in particular in innate immune 177 
signaling and T cell activation and differentiation [2]. Even though most genetic variants that 178 
confer AD susceptibility have relatively small effect sizes, they have provided important 179 
insights into the biology of the disease and subsequently supported the genetic basis for 180 
established drugs [47] and identified potential drug targets for allergic diseases [10]. 181 
 182 
Since the first GWAS in 2009, large scale collaborations have made progressively larger 183 
sample sizes available, and the process of predicting genotypes through imputation, a method 184 
to estimate the genotype at genetic markers that not are directly genotyped, is commonly 185 
used. In 2015, the EAGLE consortium meta-analyzed >15 million genetic variants in 21,399 186 
cases and 95,464 controls [47]. Their replication phase included 32,059 cases and 228,628 187 
controls. The study included populations of European, African, Japanese and Latino ancestry, 188 
and identified ten new risk loci, increasing the total number of known AD risk loci to 31 [47]. 189 
Of the identified loci, several are common for other atopic conditions (asthma, allergic 190 
sensitization, self-reported allergy), supporting common atopic mechanisms [47]. This was 191 
further investigated by Ferreira et al., where genetic risk factors were identified between 192 
asthma, hay fever and eczema [10]. They identified 136 independent risk variants, of which 193 
73 were novel; disease-specific effects were detected for only six variants, confirming shared 194 
genetic risk across atopic phenotypes. The risk variants were shown to dysregulate the 195 
expression of immune-related genes [10]. These results were further explored using gene-196 
based tests and additional 11 risk loci for allergic diseases were discovered [11]. 197 
 198 
3.4 Phenome-wide association studies (PheWAS). While GWAS analyze thousands to 199 
millions of genetic variants per phenotypic trait, PheWAS inverts this study design to analyze 200 
many phenotypic traits for association with a single genetic variant. The goal of this study 201 
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design is to elucidate genetic variants with multiple phenotype relationships (e.g. 202 
comorbidities and pleiotropy) [51]. The method has also successfully been used for drug 203 
discovery and repositioning, prediction of adverse drug events and selection of indications for 204 
clinical trials [52, 53]. Figure 2 shows the results of a PheGWAS analysis on the UK Biobank 205 
PheWeb (http://pheweb.sph.umich.edu:5003) based on GWAS of 28 million variants across 206 
1,403 ICD-derived traits identified in 408,961 individuals [54] for the lead variant 207 
(rs61816761) within the FLG gene. As expected and due to known atopic comorbidities, we 208 
find that this genetic variant is associated with asthma, dermatitis, and allergic reaction to 209 
food (the latter only nominally significant). This variant is also associated with diseases of 210 
sebaceous glands, a result that is suggestive of pleiotropy or shared disease mechanisms.  211 
 212 
3.5 Genetic sequencing studies. To date, GWAS has mainly been conducted using genotype 213 
arrays that are designed to measure genetic variation at common variants. Imputation allows 214 
for estimation of genotypes of rare variants not included on genotyping arrays, but this is 215 
dependent on the size and quality of the imputation reference panel. By their nature, rare 216 
variants are so infrequently seen that those detected often do not reach statistical significance 217 
in GWAS, even in large sample sizes. Due to this, rare genetic variants (population minor 218 
allele frequency typically <1%) have not yet been investigated to the same extent as common 219 
variants, even though they may have from moderate to high effects on complex traits [55, 56]. 220 
Facilitated by the steady drop in sequencing costs, large-scale studies of rare variants are now 221 
possible through both whole-exome sequencing (WES) and whole-genome sequencing 222 
(WGS). WES targets all of the protein-coding regions of the genome (known as the exome) 223 
and has proven to be a useful tool to investigate rare diseases and in the search for rare 224 
variants causing polygenic diseases [55]. For AD, the WES studies performed to date have 225 
had relatively small sample sizes [57-62]. The first published study included 22 Ethiopian 226 
individuals with ichthyosis vulgaris and AD, and identified several rare variants suggesting a 227 
heterogenous disease pathogenesis [57]. Recently, 43 probands of 42 Bangladeshi families 228 
with severe AD were investigated using WES in combination with rare variant enrichment 229 
analysis [60]. This identified a rare putative loss-of-function allele in FLG as the major 230 
component of disease susceptibility, in addition to potential novel risk genes within 231 
chromosome 1 (TCHHL1, ADCY10, MTF1, MAST2), 6 (SCAND3), 9 (ORM2), 10 (MCM10), 232 
11 (PHLDB1, PANX3) and 12 (CUX2) [60]. Further, WES showed that dominant negative 233 
loss-of-function mutations in CARD14 were associated with severe AD [62]. Upregulation of 234 
the same gene leads to psoriasis [63, 64], in line with previously identified shared loci with 235 
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opposing mechanisms for psoriasis and AD [48]. Larger and population-based WES and 236 
WGS to systematically investigate less frequent genetic variations and association to disease 237 
are ongoing in several cohorts [65]. In October 2018, it was announced that the United 238 
Kingdom’s National Health Services (NHS) are currently planning to sequence the genomes 239 
of one million people, and in the next five years, they are planning to sequence five million 240 
genomes [66].  241 
 242 
4. Investigating causal relationships using Mendelian Randomization (MR) 243 
Causal relationships can be investigated with MR, a method that uses genetic variants to make 244 
causal inference of non-genetic environmental exposures [67]. These studies leverage 245 
Mendel’s second law that the inheritance of one trait is independent of other traits. When 246 
satisfied, genetic variants can be used as instrumental variables to estimate causal effects. 247 
Additional, germline genetic variants are fixed at conception and this happens prior to the 248 
onset of disease, therefore these analyses are less susceptible to confounding and reverse 249 
causality [67, 68]. Through GWAS, the increasing identification of genetic determinants of 250 
modifiable exposures and phenotypes has provided a valuable source of data to use for MR 251 
analyses. Examples of MR used in dermatology include investigations of direction(s) of 252 
causality for psoriasis with higher CRP levels (supports a non-causal relationship) [69] and 253 
higher body mass index (BMI) (supports a causal relationship) [70, 71]. For AD, the 254 
relationship to lower vitamin D levels and AD has been tested and evidence indicates a non-255 
causal relationship [72]. Observational epidemiological studies have reported an association 256 
of high BMI with risk of AD [73]. If high BMI is a causal risk factor for AD this may have 257 
implications for treatment and prevention strategies because BMI is potentially modifiable. 258 
An ongoing MR study is examining this potential causal relationship (unpublished data). The 259 
study population includes >400,000 individuals from the UK Biobank and the Nord-260 
Trøndelag Health Study (The HUNT Study) and genetic variants identified by GWAS to be 261 
associated with BMI and AD as instrumental variables.  262 
 263 
5. Translation into clinical relevance  264 
The results of MR studies as described above may have implications for treatment and 265 
prevention strategies for AD. Further, genetic information leading to focus on skin barrier 266 
dysfunction as the key precursor to increased skin permeability, inflammation and 267 
percutaneous allergic sensitization [5] have given rise to the development of novel treatment 268 
strategies that target the skin barrier or cutaneous inflammation [15, 16]. However, despite an 269 
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increasing knowledge about disease mechanisms, there is still a very limited number of 270 
systemic immunomodulating biologics that have been approved for the treatment of 271 
moderate-to-severe AD [74]. One exception is Dupilumab, a fully human monoclonal 272 
antibody targeting the IL-4 and Il-13 pathway [75]. Dupilumab was the first biologic to 273 
receive US Food and Drug Administration (FDA) and European Medicines Agency (EMA) 274 
approval for the treatment of adults with moderate-to-severe AD. Clinical trials have shown 275 
that Dupilumab significantly improved clinical outcomes and quality of life in adults with 276 
moderate-to-severe AD [76]. Many other new treatments are under development with several 277 
biologics and small molecule antagonists in phase II and phase III trials [2].  278 
 279 
AD shows large clinical heterogeneity, and a recent study divided AD into six sub-280 
phenotypes, which showed different risk profiles and diverse prognosis [77]. With the 281 
increasing knowledge of genetic associations with AD in combination with the steady drop in 282 
genotyping costs, one can foresee a future where health care providers could have access to 283 
the patient’s genetic data [78]. Personal genetics could help stratifying individuals into AD 284 
disease subsets, and direct medical interventions by making predictions about disease risk, 285 
tailoring the right therapeutic strategy and prevention programs for the right person at the 286 
right time ('the promise of precision medicine'). This could again reduce the risk of adverse 287 
events and the costs related to treatments. For AD, genetic risk could be ascertained from 288 
birth, and thereby identify individuals at risk for atopic diseases. Such knowledge could allow 289 
early interventions to prevent disease, e.g. using daily emollients to enhance a defective skin 290 
barrier [79, 80]. It has been suggested that early preventive treatments of AD could reduce the 291 
development of associated comorbidities, such as asthma [15]. To calculate a polygenic risk 292 
score per individual for AD could be a method of identifying individuals for preventive 293 
measures. A polygenic risk score adds together the contributions of all the small genetic 294 
effects as estimated through GWAS and provides a continuous and quantitative measure of 295 
genetic risk [81]. Polygenic risk scores could create one of the most powerful genetic 296 
diagnostics to date, such as demonstrated for e.g. coronary artery disease and atrial fibrillation 297 
[82]. To date, there is no routine in integration of genetic testing in the clinics for 298 
inflammatory skin disease. However, work to predict individual treatment responses in 299 
dermatology is ongoing through e.g. the Psoriasis Stratification to Optimize Relevant Therapy 300 
(PSORT) consortium [83]. 301 
 302 
6. Mind the gap  303 
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Despite the success of association analyses among complex diseases [42], there is still a 304 
significant proportion of genetic risk that has not yet been explained for most traits. This 305 
phenomenon has been called the 'missing heritability' of complex diseases [84, 85]. For AD, 306 
the identified GWAS loci explains approximately 15% of the variance in liability [47], which 307 
is in line with other highly heritable complex traits. There are many factors that could explain 308 
this still 'missing heritability' ten years after the first large scale GWAS. This includes effects 309 
due to marked heterogeneity of AD, the cumulative effects of multiple genetic variations, rare 310 
genetic variations, structural variations of the genome such as copy number variants (CNV), 311 
the existence of gene-gene and/or gene-environment interactions, and heritable epigenetic 312 
mechanisms [26]. The present times are highly promising for investigating more of these 313 
effects. 314 
 315 
Technological advances have opened new possibilities for analyzing multi-omics data [86]. 316 
The likelihood of identifying a true gene or pathway increases if data from multiple levels of 317 
biological data support the same association [86]. By multi-staged and meta-dimensional 318 
analyses of multi-omics one could identify effective models that predict disease status, 319 
discover biomarkers and lead to an increased understanding of the role of genetics and 320 
genomics in complex traits [86] and in AD in specific [25, 39]. Multiple levels of biological 321 
data are illustrated in Figure 3 (adapted from [86]), and includes data from the genome, 322 
epigenome, transcriptome, proteome and metabolome.  323 
  324 
7. Conclusions 325 
Over the last decade there has been a paradigm shift in our understanding of the mechanisms 326 
causing AD. Moving away from a purely immunological view, genetic studies have played a 327 
major role in understanding defects of the epidermal barrier. In the future we hope for similar 328 
mechanistic breakthroughs lead by gene discoveries, that these discoveries will continue to 329 
inform drug development efforts and safety measures, and that personal genetic information 330 
may be included in routine clinical care to aid prevention and treatment of AD. The 331 
groundwork for these implementations is the growing large-scale high-throughput genomics, 332 
including both WES and WGS, made possible by population-based biobanks in combination 333 
with information from electronic health records, and methods developed to handle these 334 
complex health data with the necessary computational and statistical expertise [65]. Together 335 
such activities will increase the interpretation and functional validation, and future studies 336 
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will most likely take gene-gene and gene-environmental effect into larger account and include 337 
multi-omics technologies.  338 
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14. Figures and Legends 596 
 597 
 598 
 599 
 600 
Fig. 1. Some of the investigative strategies that can be used to increase the knowledge of 601 
molecular mechanisms involved in a phenotypic trait. Candidate gene studies are performed 602 
on genes that are suggested to be involved in the genesis of a phenotypic trait because of their 603 
theoretically role in the trait being investigated. Genome-wide studies include genome-wide 604 
association studies (GWAS) and genetic sequencing studies. GWAS are mainly conducted in 605 
large population-based samples using genotype arrays that are designed to measure genetic 606 
variation at common variants. Genetic sequencing studies includes both whole-exome 607 
sequencing (WES) and whole-genome sequencing (WGS). WES targets all of the protein-608 
coding regions of the genome, and WGS targets the complete genome sequence. The results 609 
of candidate gene and genome-wide studies can be used in phenome-wide association studies 610 
(PheWAS) that analyze many phenotypic traits for association with a single genetic variant to 611 
test multiple phenotype relationships, and further, they could be used as instrumental 612 
variables in Mendelian Randomization (MR) studies for the investigation of causal 613 
relationships.  614 
 615 
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 618 
 619 
Fig. 2. PheGWAS plot of the lead variant (rs61816761) in FLG in UK Biobank. The variant is 620 
associated with dermatitis (P value 3,2 x 10-10) in 2,110 cases and 40,4817 controls. As 621 
expected, the variant is also associated with asthma (P value 5 x 10-12) and nominally 622 
associated with allergic reaction to food (P value 5,8 x 10-5). The genetic variant is further 623 
associated to diseases of sebaceous glands (P value 2,1 x 10-7) and sebaceous cyst (P value 624 
4,6 x 10-7). 625 
 626 
 627 
 628 
 629 
Fig. 3. Technological advances have made efficient integration of multi-omics possible. This 630 
includes combined studies of the genome, epigenome, transcriptome, proteome and 631 
metabolome and the observed phenome. Adapted from [86]. 632 
